ALLMedicine™ Gastrointestinal Stromal Tumors Center

Mar 28th, 2023 - Imatinib mesylate (IM) is the standard chemotherapy for patients with gastrointestinal stromal tumors (GISTs) and has a favorable safety profile. Pharmacokinetics (PK), such as plasma trough concentration (Cmin), varies among patients, requiring t...

Mar 27th, 2023 - Dysregulated expression of heat shock proteins (HSP) plays a fundamental role in tumor development and progression. Consequently, HSP90 may be an effective tumor target in oncology, including the treatment of gastrointestinal cancers. We carried o...

Mar 26th, 2023 - Gastrointestinal stromal tumors (GISTs) are the prevailing sarcomas of the gastrointestinal tract. Tyrosine kinase inhibitors (TKIs) therapy, exemplified by Imatinib mesylate (IM), constitutes the established adjuvant therapy for GISTs. Neverthele...

Mar 25th, 2023 - The immune landscapes of gastrointestinal stromal tumors (GISTs) are still unclear. We aimed to explore the immune status of GISTs with different recurrence risks and sought potential immunotherapeutic targets. Immune cell infiltration and the exp...

Mar 25th, 2023 - Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors. They are most frequently located in the stomach but are also found in the esophagus and the gastroesophageal junction (GEJ). Information regarding the prognostic factors associate...

Dec 26th, 2018 - Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or conse...

Jul 30th, 2014 - The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-even...

Nov 20th, 2012 - Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2012| ,|therapeutic use,diagnosis,genetics,therapy,diagnosis,genetics,therapy,therapeutic use,therapeutic use,

May 9th, 2008 - Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.|2008|Casali PG,Jost L,Reichardt P,Schlemmer M,Blay JY,|diagnosis,epidemiology,pathology,therapy,

Mar 21st, 2023 - Background: Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal soft tissue sarcoma, but remain a rare disease entity. Most GISTs are characterized by KIT or PDGFRA mutations, making them susceptible to tyrosine kinase inh...

Feb 10th, 2023 - Imatinib can lead to long recurrence free survival in patients diagnosed with gastrointestinal stromal tumors (GIST); however side effects can significantly hinder quality of life for our patients. This study will use therapeutic drug monitoring t...

Feb 8th, 2023 - This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 426 patients. Part 1 consists of two evaluations: 1) confirming the dose of an upda...

Feb 8th, 2023 - Regorafenib is an oral tumour deactivation agent that potently blocks multiple protein kinases, including kinases involved in tumour angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600E), metastasis (VEGFR3, PDGFR, FG...

Feb 6th, 2023 - The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST), recurrent gliomas, or othe...

Jan 27th, 2023 - Circulating tumor DNA (ctDNA) analysis of KIT mutational status may be able to guide second-line treatment in patients with imatinib-resistant gastrointestinal stromal tumors (GIST), according to an exploratory analysis from the INTRIGUE trial. Sp...

Jan 6th, 2023 - Identifying risk factors for "reconstructive burnout" may help reduce the number of patients who begin reconstruction surgery after breast cancer treatment but do not complete the process. (Plastic and Reconstructive Surgery) Individualized brachy...

Oct 6th, 2022 - The proper management of subepithelial lesions (SELs) depends on the size, histopathology, malignant potential, and presence of symptoms, according to a new American Gastroenterological Association clinical practice update published in Clinical Ga.

Sep 13th, 2022 - Among the many drugs now available for the treatment of advanced gastrointestinal stromal tumors (GIST), where does the relative newcomer ripretinib (Qinlock) fit in ? This is the question posed in an editorial recently published in the Journal of...

Sep 6th, 2022 - Welcome to OncLive On Air®! I’m your host today, Caroline Seymour. OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital an...